Systemic corticosteroids for outpatient respiratory viral infections in lung transplant recipients

IntroductionRespiratory viral infections (RVI) in lung transplant recipients (LTR) have variably been associated with rejection and chronic lung allograft dysfunction. Our center has used systemic corticosteroids to treat outpatient RVI in some cases, but evidence is limited. We reviewed all adult LTR diagnosed with outpatient RVI January 2017 to December 2019. The primary outcome was recovery of lung function (forced expiratory volume in 1 s [FEV1]) at next stable visit between 1 and 12 months postinfection, expressed as a ratio over stable preinfection FEV1 (FEV1 recovery ratio).MethodsWe identified 100 adult LTR with outpatient RVI diagnoses eligible for study, 36% of whom received corticosteroids. We modelled the adjusted association between corticosteroid use and FEV1 recovery ratio using linear regression.ResultsSteroid-treated patients had a lower FEV1 presentation ratio (0.92 vs. 1.04, p = .0070) and were more likely to have chronic lung allograft dysfunction at time of infection (25% vs. 5%, p = .0077). Mean FEV1 recovery ratio was 1.02 (SD 0.19) with no association with corticosteroid therapy via multivariable linear regression (p = .5888).ConclusionsSteroid treatment was not associated with FEV1 recovery. This suggests corticosteroids may not have a role in the management of RVI in this population.image In our cohort of 100 lung transplant recipients with respiratory viral infection, systemic corticosteroids were not associated with a difference in the probability of lung function recovery, which was mainly determined by lung function loss at the time of infection. A clinical trial is warranted to definitively evaluate this therapy.image

Automated summary

In our cohort of 100 lung transplant recipients with respiratory viral infection, systemic corticosteroids were not associated with a difference in the probability of lung function recovery, which was mainly determined by lung function loss at the time of infection. A clinical trial is warranted to definitively evaluate this therapy.